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BACKGROUND: Diabetes mellitus is unfavorably associated with cancer risk. The purpose of this multi-
disciplinary project was to evaluate a possible association of diabetes mellitus and other comorbidities and
their treatment with progression of colorectal cancer. PATIENTS AND METHODS: We investigated the correlation
between pathological characteristics and clinical course, including comorbidities in 1004 Czech patients
diagnosed and surgically treated for colorectal adenocarcinoma (CRC) between 1999 and 2016. RESULTS: In our
data set, CRC patients treated with metformin due to coexisting diabetes mellitus type 2 (T2DM) developed fewer
distant metastases which clinically correlates with slower CRC progression. Survival in metformin subgroup was
longer, particularly in men with CRC. Osteoporosis may be a negative factor of survival in CRC patients.
CONCLUSIONS: Our findings also indicate that aging, higher tumor grade and TNM stage, coexistence of
selected endocrine disorders, and metabolic abnormalities may change the tumor microenvironment and impact
survival in colorectal cancer, although mechanism of these observations yet to be explained. Patients with
diabetes mellitus type 2 treated with metformin may represent the altered microenvironment with specifically© 2019 The Authors. Published by Elsevier Inc. on behalf of Neoplasia Press, Inc.




384 Survival in colorectal adenocarcinoma in response to metformin Powell et al. Translational Oncology Vol. 13, No. 2, 2020tuned metabolic molecular responses and with various epigenetic characteristics. More awareness and increased
understanding of the mechanisms underlying the positive effect of metformin on patients' survival could offer
insight into new treatment methods and permit more individualized treatment plans.
Translational Oncology (2020) 13, 383–392Introduction
Colorectal cancer (CRC) is frequently diagnosed malignancy world-
wide and continues to be a serious cause of morbidity and mortality
despite ongoing screening efforts [1]. According to NIH National
Cancer Institute statistics, approximately 1 in 22 men and 1 in 24
womenwill be diagnosedwith CRC in their lifetime. Five-year survival
2008e2014 in the United States was 64.5%. CRC affects both sexes
most commonly in the 6th decade of life but the proportion of cases
diagnosed in individuals younger than 50 years of age increased to 11%
in 2013 [2]. In Czech Republic, the incidence follows the worldwide
trend [3].
It is known that CRC can develop as a result of accumulated
genetic mutations over time similar to other malignancies or silencing
tumor suppressor genes in Li-Fraumeni syndrome, although most of
CRC cases are the consequence of chromosomal and microsatellite
instability and their course and aggressiveness are consequent to
epigenetic characteristics [4]. Diabetes mellitus together with obesity
and increased level of adipocytokines, fasting hyperglycemia, insulin
resistance and hyperinsulinemia, chronic inflammation, and recurrent
increased level carcinoembryonic antigen are all thought to play a role
in the increased risk for CRC progression and death. All of these
characteristics are considered to be negative prognostic factors [5e8].
A number of retrospective studies dealing withCRC in patients with
diabetes have been published but were clearly underpowered to detect
possible subtle interrelationships between treatment details and
patients' survival. It has been proposed that glycemic load adverse
effects correlate with recurrence and survival of CRC stage III in recent
observational prospective studies [9,10]. Publications based on
metaanalyses of large data sets showed up to 44% overall survival
benefit inmetformin-treatedCRCpatients with stages IeIII [11e13].
Phosphorylated insulin receptors together with increased blood
level of IGF1 possibly play a role in development of metastases in
CRC which correlates with poor prognosis. The nuclear location of
IGF-1R has been observed in chemotherapy resistance [14,15].
The course of CRC and survival may be affected not only by the
pathophysiological systemic effects of T2DM but adversely by action
of peroral antidiabetics (PAD). Biguanides (metformin, phenformin,
and buformin) are derived from the herbGalega officinalis. Metformin
was developed as therapy for T2DM in the 1950s. It works via
inhibition of hepatic gluconeogenesis and increased uptake of glucose
in muscle. In malignant cells, metformin action includes LKB1-me-
diated activation of AMPK, inhibitingmTORC1 signaling, and affects
liver homeostasis and metastatic development [16e18]. It has been
published that glucose level impacts various cellular morphoproteomic
changes (via Sirt1, PIAS1, STAT1, MRP1, mTOR) with adequate
consequences for tumor growth as well as metastatic progression [19].
United Kingdom prospective prevention diabetes study suggests
that metformin also works by mechanism of insulin resistance in liver,
by bile acids metabolism, incretins release, and decrease deposit ofamyloid in metformin users [20]. Some studies observed a 15e30%
increased survival of CRC patients treated with metformin compared
with patients on other antidiabetic agents [21,22]. Other studies
which attempted to avoid the potential confounders of adjuvant
therapy, focused more on stratified patients by TNM stage, did not
show any effect of metformin on the course of CRC. Recent
prospective studies suggested at least a 15% decrease in risk of
all-cause mortality in CRC patients with T2DM treated with
metformin compared with patients receiving insulin [23e26].
Thyroid hormone substitution in patients with clinical hypothyr-
oidism seems to have protective effects concerning CRC progression
[27] when assessing circulating levels of thyroid hormones or receptor




We identified 1004 Caucasian patients diagnosed with colon and
rectal adenocarcinoma in four Czech hospitals between January 1,
1999, and June 30, 2016. In 770 cases, comprehensive clinical data
were available. 234 patients were excluded (due to missing lab or
clinical data e.g. oncology treatment details, if a statistically
insufficient number of CRC patients with specific comorbidity was
identified e.g. with neurodegenerative diseases, and because of insulin
therapy exclusion criteria). 189 patients were lost to follow-up in one
year, and 548 patients were lost to follow-up within five years after
CRC diagnosis. The participating institutions were two major
hospitals in Prague (General University Hospital, Na Bulovce
Hospital) and two regional hospitals, one in the most northern part
of the country (Jablonec nad Nisou) and the other in the most
southern part of the country (Jindrichuv Hradec). The pathological
and clinical data were carefully collected by hand from online records
of the healthcare institutions and analyzed retrospectively.
Compliance with Ethical Standards
The study was approved by the Ethics Committee of Na Bulovce
Hospital (EK NNB 30.6.2014/7248/EK-Z on September 4, 2014),
Hospital Jablonec nad Nisou (LEK 9/2016/St on November 15,
2016), General University Hospital, Prague (158/15 S-IV on March
19, 2015), and Hospital Jindrichuv Hradec (approval was not
numbered on February 3, 2015). All procedures involving human
participants were in accordance with the ethical standards of the
institutional Ethical Committees and with the 1964 Helsinki
declaration and its later amendments or comparable ethical standards.
Definitions
Cases of adenocarcinoma histology C18.0eC20.9 were included.
Primary tumors were located in all parts of large intestine: left colon,
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rectum; we also recorded rare locations in appendix and Meckel's
diverticulum. Five cases of ulcerative colitis and seven cases of Lynch
syndrome were found in the data set. The day of surgical resection
was considered the day of diagnosis although the disease was always
verified by colonoscopy and biopsy a short time prior to resection.
The resected specimens were routinely described macroscopically,
including tumor location and size. The fat surrounding the large
intestine was left overnight in Carnoy's solution to identify all
lymphatic nodes. The resection margin was examined.
Hematoxylineeosin staining was used for histologic study and the
slides were evaluated using light microscopy by board-certified
pathologists. Histopathology evaluation consisted of tumor type,
grade, and TNM stage [29].
Collected Data
We recorded the following: a) Age and sex of the patient; b)
Location and size of the tumor; c) Histopathology: tumor type; grade;
growth pattern; stroma type (desmoplastic, mucinous, fibroproduc-
tive, with chronic inflammatory cells); d) Pathological TNM staging
combined with clinical data about distant metastases; e) Local
recurrence and distant metastases; f) Chemotherapy and radiation
data; g) Laboratory values including glucose, creatinine, liver
enzymes; h) Last follow-up; i) Death (number of months after
diagnosis and the cause related or unrelated to CRC); j) T2DM
subgroups according to treatment regimens: diet, insulin, metformin,
other oral antidiabetics (gliclazide, glimepiride, glibenclamide); k)
Hypothyreosis; l) Other endocrine disorders: struma nodosa and
status poststrumectomy, hyperparathyroidism and hyperaldosteron-
ism, adenoma of hypophysis, thyroid, parathyroid, and subrenal
glands, adrenal hyperplasia, status postovarectomy, and hormone
replacement therapy (HRT) in women, status postorchiectomy and
prostatectomy, mastopathy in men, abnormal glucose tolerance; m)
Autoimmune diseases: chronic atrophic thyroiditis, hepatitis and
gastritis, rheumatoid arthritis, psoriasis, and sarcoidosis; n) Metabolic
syndrome: obesity, steatohepatitis, hyperlipidemia; o) Osteoporosis
(age >65 and clinical statement).
The strengths of this study are consistent data collection that was
performed by the same person in all four centers, and multi-
disciplinary approach. The access to correlating CRC specimens
(paraffin blocks) can be advantageous for morphoproteomic studies in
the future. On the other hand, some data were not available as some
patients were operated on in the university surgical center but they
continued to have oncology treatment and follow-up in smaller
hospitals out of our reach. Despite our effort, some subgroups of
patients are small (including with metformin treatment) and for that
reason not all results are statistically significant, which needs to be
taken into account when making clinical and scientific judgment on
outcomes of this study.
Statistical Methods
The main aim of the study was to explore the impact of different
disorders on the overall survival of patients with CRC. Data
preprocessing, including cleaning, was applied before analysis.
Continuous variable (age) was characterized by the average, minimum,
andmaximum. Categorical variables were described as frequencies and
the relative frequencies of individual variants. In univariate analysis
was to compare the characteristics of subjects with and without
T2DM, respectively, with and without metformin use, for character-istics measured on the nominal scale, the Yates chi-squared test was
used. The Cox proportional hazards (PH) regression model was used
to evaluate the effect of different clinical and pathologic parameters on
survival and generate hazard ratios for death. The estimated
parameters with the standard error of these parameters, hazard ratios,
and corresponding confidence intervals and p-values are listed.
In 770 evaluated cases with CRC there were 99 deaths from
progression of colorectal carcinoma. Figures display the
KaplaneMeier curves for the compared groups and the p-values of
the log-rank tests. KaplaneMeier curves do not go all the way down
to zero when the largest observed time (which is around 15 years) is
censored. P-values less than 0.05 indicate that there is statistical
significant difference between the populations (compared groups) in
the probability of a death by colorectal carcinoma at any time point.Results
Our data set consists of data on 483 (62.7%) men and 287 (37.3%)
women. The age range was 31e95 years, the average age 68 years.
The pathological and clinical findings are summarized in Table 1.
Survival analyses in Table 2.
A survival model for patients with diabetes mellitus was designed to
determine the possible effect of metformin use on the survival
probability. The estimated parameters with the standard error of these
parameters, hazard ratios, and corresponding confidence intervals and
p-values are shown in Table 4. The estimated hazard rates of dying
(statistically significant different from constant 1) are listed as well.
The goodness-of-fit for the chosen model was performed by the score
log-rank test with significant p-value (less than 0.001).
In 118 patients with CRC and T2DM, there were 14 deaths
because of progression of colorectal carcinoma. Figures display the
KaplaneMeier curves for the compared groups and the p-values of
the log-rank tests. KaplaneMeier curves do not go all the way down
to zero when the largest observed time (which is around 11 years for
metformin users and around 12 years for patients with diet or other
PAD) is censored. P-values less than 0.05 indicate that there is
statistical significant difference between the populations (compared
groups) in the probability of a death by colorectal carcinoma at any
time point.
Survival analyses in Table 4.
In concordance with current pathological and clinical experience,
survival reflected most significantly aging, higher tumor grade, and
TNM stage (Table 1 and Figure 2A). The most frequent comorbidity
in CRC in our data set was diabetes mellitus type 2 with prevalence of
16.8% in men and 12.9% in women. T2DM was treated with diet,
other PAD, and metformin (Table 3, Figure 3A and B).
The survival analysis showed no difference between men and
women with CRC in total pool of data (Figure 1A). Better survival,
important for prognosis, is seen in men with CRC, particularly in the
subgroup treated with metformin due to T2DM (Figure 1B). Patients
treated with metformin also developed fewer distant metastases
(5.6%) if CRC progressed later compared with subgroup of CRC
patients without metformin therapy (17.2%) and these results were
statistically significant (Table 3).
CRC is a highly heterogenous carcinoma and therapies targeting
different cellular pathways are expected to have various final effects.
Some publications promote rectal adenocarcinoma as a separate
category from colonic adenocarcinoma pathogenetically and by
progression [30]. Although generally the tumors develop in right and
left colon equally, our data suggest most CRC primary tumors were
Table 1. Characteristics of CRC Patients with Coexisting T2DM. Statistical Significance of Differences (Univariate Analysis) Is Shown in Bold.
Characteristics All Patients (n ¼ 770) With T2DM (n ¼ 118) Without T2DM (n ¼ 652) Chi-square Test (p)
Total Known Deaths 178 (23.1%) 31 (26.3%) 147 (22.5%) 0.445
Gender
Men 483 (62.7%) 81 (68.6%) 402 (61.7%) 0.178
Women 287 (37.3%) 37 (31.4%) 250 (38.3%)
Age
<60 167 (21.7%) 8 (6.8%) 159 (24.4%) <0.001
>60 603 (78.3%) 110 (93.2%) 493 (75.6%)
Primary Tumor Location
Left colon 356 (46.2%) 52 (44.1%) 304 (46.6%) 0.371
Right colon 207 (26.9%) 31 (26.3%) 176 (27%)
Rectum 177 (23%) 27 (22.9%) 150 (23%)
Transversum colon 30 (3.9%) 8 (6.8%) 22 (3.4%)
Histopathology Grade
Well differentiated 173 (22.5%) 29 (24.6%) 144 (22.1%) 0.076
Moderately differentiated 503 (65.3%) 82 (69.5%) 421 (64.6%)
Poorly differentiated 94 (12.2%) 7 (5.9%) 87 (13.3%)
Morphology
Adenocarcinoma 625 (81.2%) 106 (89.8%) 519 (79.6%) 0.026
Adenocarcinoma with mucinous stroma 137 (17.8%) 12 (10.2%) 125 (19.2%)
Signet ring cell adenocarcinoma 8 (1%) e 8 (1.2%)
pTNM Stage
In situ 5 (0.6%) 1 (0.8%) 4 (0.6%) 0.724
I 36 (4.7%) 7 (5.9%) 29 (4.4%)
II 156 (20.3%) 21 (17.8%) 135 (20.7%)
III 474 (61.6%) 77 (65.3%) 397 (60.9%)
IV 99 (12.9%) 12 (10.2%) 87 (13.3%)
Lymphatic Nodes at Time of Resection
With metastases 331 (43%) 49 (41.5%) 282 (43.3%) 0.805
Without metastases 439 (57%) 69 (58.5%) 370 (56.7%)
Distant Metastases
Without metastases 578 (75.1%) 87 (73.7%) 491 (75.3%) 0.861
At least one (at resection time) 99 (12.9%) 17 (14.4%) 82 (12.6%)
At least one (later) 93 (12.1%) 14 (11.9%) 79 (12.1%)
Type of CRC Comorbidities
Osteoporosis 339 (44%) 69 (58.5%) 270 (41.4%) 0.001
Metabolic syndrome 131 (17%) 31 (26.3%) 100 (15.3%) 0.006
Hypothyreosis 70 (9.1%) 13 (11%) 57 (8.7%) 0.537
Endocrinopathy 52 (6.8%) 5 (4.2%) 47 (7.2%) 0.325
Autoimmune diseases 27 (3.5%) 3 (2.5%) 24 (3.7%) 0.729
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colon transversum where CRC primary tumor was found in 6.8%
with T2DM versus 3.4% in nondiabetic population (Table 1).Table 2. Fitted Stochastic Cox PHModel for Overall Survival Time of CRC Patients (770 Patients,
99 Deaths for CRC).
Predictors Coef SE (Coef) HR* 95% CI for HR p
Age 0.022 0.010 1.02 (1.00; 1.04) 0.039
pTNM Stage
T ¼ In situ, I, II, III; baseline e e e e e
T ¼ IV 0.681 0.242 1.98 (1.23; 3.18) 0.005
Histopathology Grade
Grade I (well differentiated; baseline) e e e e e
Grade II (moderately differentiated) 0.333 0.330 1.40 (0.73; 2.67) 0.313
Grade III (poorly differentiated) 0.983 0.390 2.67 (1.25; 5.73) 0.012
Metastases in Lymphatic Nodes
Without metastases; baseline e e e e e
With metastases 1.145 0.248 3.14 (1.93; 5.11) <0.001
Distant Metastases
Without metastases; baseline e e e e e
At least one metastasis at resection time 1.764 0.267 5.84 (3.46; 9.85) <0.001
At least one metastasis later 1.215 0.256 3.37 (2.04; 5.57) <0.001
Score (log-rank overall) test: p < 0.001.
SE, standard error; CI, confidence interval; HR, hazard ratio.
* A positive (negative) coefficient estimate in the Cox PH model corresponds to a higher (lower) risk of
death and thus on average a shorter (longer) OS time.Right-sided tumors showed longest survival regardless any
comorbiditiesegendereage compared with CRC in left colon,
rectum, and colon transversum (Figure 2B). Here anatomy
conditions and embryology specifications, blood supply factors, and
related biochemical and molecular alterations could make the
difference and these factors are worth further investigating.
Adenocarcinoma as most frequent histological type was found in
>80%, followed in frequency by adenocarcinoma with mucinous
type of stroma with content <50% of mucin in histology (Table 1).
Signet ring cell tumor representing intracellular mucin involvement
was diagnosed in patients in nondiabetic patients in 1.2% vs. none
patients with T2DM (Table 1). Poorly differentiated primary tumors
were least frequent in CRC patients without T2DM; however, this
group of patients was small (Table 1) and it is difficult to comment on
any possible correlation on overall CRC survival in diabetic and
nondiabetic population based on tumor morphology features.
Overall survival in CRC patients with osteoporosis was shorter and
coexisting other endocrinopathies (Materials and methods/Collected
data and Table 1) correlated with longer survival in CRC patients
(Figure 4A and B), although the subgroup of patients with these
disorders was small and affected the statistical significance. Coexisting
osteoporosis was present in 50% of CRC cases with one distant
metastasis at time diagnosis and in 30% of CRC cases with at least
one metastasis developed later (Figure 5).
Table 3. Characteristics of Patients with T2DM Depending on Coexisting Metformin Treatment. Statistical Significance of Differences (Univariate Analysis) Is Shown in Bold.
Characteristics Patients with DM2T (n ¼ 118) Patients with Metformin Treatment (n ¼ 54) Patients without Metformin Treatment (n ¼ 64) Chi-square Test (p)
Total Known Deaths by CRC 14 (11.9%) 2 (3.7%) 12 (18.8%) 0.026
Gender
Men 81 (68.6%) 36 (66.7%) 45 (70.3%) 0.821
Women 37 (31.4%) 18 (33.3%) 19 (29.7%)
Age
<60 8 (6.8%) 2 (3.7%) 6 (9.4%) 0.393
>60 110 (93.2%) 52 (96.3%) 58 (90.6%)
Primary Tumor Location
Left colon 52 (44.1%) 23 (42.6%) 29 (45.3%) 0.621
Right colon 31 (26.3%) 12 (22.2%) 19 (29.7%)
Rectum 27 (22.9%) 15 (27.8%) 12 (18.8%)
Transversum colon 8 (6.8%) 4 (7.4%) 4 (6.3%)
Histopathology Grade
Well differentiated 29 (24.6%) 14 (25.9%) 15 (23.4%) 0.632
Moderately differentiated 82 (69.5%) 38 (70.4%) 44 (68.8%)
Poorly differentiated 7 (5.9%) 2 (3.7%) 5 (7.8%)
Morphology
Adenocarcinoma 106 (89.8%) 49 (90.7%) 57 (89.1%) >0.999
Adenocarcinoma with mucinous stroma 12 (10.2%) 5 (9.3%) 7 (10.9%)
Signet ring cell adenocarcinoma e e e
pTNM Stage
In situ 1 (0.8%) 1 (1.9%) e 0.405
I 7 (5.9%) 3 (5.6%) 4 (6.3%)
II 21 (17.8%) 12 (22.2%) 9 (14.1%)
III 77 (65.3%) 31 (57.4%) 46 (71.9%)
IV 12 (10.2%) 7 (13%) 5 (7.8%)
Lymphatic Nodes at Resection
With metastases 49 (41.5%) 21 (38.9%) 28 (43.8%) 0.729
Without metastases 69 (58.5%) 33 (61.1%) 36 (56.3%)
Distant Metastases
Without metastases 87 (73.7%) 45 (83.3%) 42 (65.6%) 0.067
At least one (at resection time) 17 (14.4%) 6 (11.1%) 11 (17.2%)
At least one (later) 14 (11.9%) 3 (5.6%) 11 (17.2%)
Type of CRC Comorbidities
Osteoporosis 69 (58.5%) 30 (55.6%) 39 (60.9%) 0.687
Metabolic syndrome 31 (26.3%) 14 (25.9%) 17 (26.6%) >0.999
Hypothyreosis 13 (11.0%) 6 (11.1%) 7 (10.9%) >0.999
Endocrinopathy 5 (4.2%) 3 (5.6%) 2 (3.1%) 0.846
Autoimmune diseases 3 (2.5%) 2 (3.7%) 1 (1.6%) 0.881
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It is known that clinical outcomes in CRC patients are affected by
some comorbidities. The better outcome in patients younger than 60
years of age could be result of a lower incidence of comorbidities
compared with older patients, a better physical condition, the abilityTable 4. Fitted Stochastic Cox PH Model for Overall Survival Time of Patients with T2DM and
CRC (118 Patients, 14 Deaths for CRC).
Predictors Coef SE (Coef) HR* 95% CI for HR p
Age 0.086 0.041 1.09 (1.01; 1.18) 0.033
Metformin
Diet or other PAD e e e e e
Metformin 2.367 0.841 10.64 (2.02; 55.55) 0.005
Metastases in Lymphatic Nodes
Without metastases; baseline e e e e e
With metastases 1.501 0.714 4.49 (1.11; 18.17) 0.036
Distant Metastases
Without metastases; baseline e e e e e
At least one metastasis at
resection time
2.357 0.715 10.56 (2.60; 42.90) 0.001
At least one metastases later 0.153 0.860 1.16 (0.22; 6.29) 0.859
Score (log-rank overall) test: p < 0.001.
SE, standard error; CI, confidence interval; HR, hazard ratio.
* A positive (negative) coefficient estimate in the Cox PH model corresponds to a higher (lower) risk of
death and thus on average a shorter (longer) OS time.to adhere to treatment more consistently, and perhaps stronger
support of peers and family. Diabetes mellitus increases the risk for
development of cancer [31]. Patients with a self-reported history of
T2DM should be also considered at higher risk for cancer [32]. With
the increasing worldwide prevalence of diabetes mellitus, a higher
incidence of CRC can be expected, along with a less favorable
prognosis for those patients on diet only for diabetes, compared with
CRC patients without diabetes and treated with PAD, with special
attention to subgroup treated exclusively with metformin (Figure 3B).
Diabetes and CRC share some risk factors related to lifestyle, such
as lack of exercise and higher body mass index, represented by
metabolic syndrome in our data set (obesity, steatohepatitis, and
hyperlipidemia). The fact that metabolic syndrome did not worsen
survival could result by high level of lipids in blood as well as in liver
controlled by therapy for it in most patients in our study. There is
evidence in preclinical studies that a high fat diet and low insulin
levels are correlated with the inhibition of tumor growth and
proliferation in CRC.
Although the pathophysiological mechanism to explain the
negative prognostic effect of diabetes has not been elucidated, clinical
and epidemiological investigations have suggested that abnormal
glucose and lipid metabolism, hyperglycemia, hyperinsulinemia,
insulin resistance in peripheral tissues, adipocytokines, long-term
chronic inflammation with IL-6, CRP and other cytokines, as well as
Figure 1. Estimated survival functions for men and women, the p-value of log-rank test comparing survival of both groups and table
of frequencies of all patients (A) and patients with T2DM treated with metformin (B).
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increased risk of CRC development [33e36].
A poorer survival of CRC patients with T2DM was observed with
poorer glycaemia controls correlating with HbA1c  7.5% and when
exogenous insulin was part of diabetic treatment, diabetes developedFigure 2. Estimated survival functions for different pTNM classif
log-rank test comparing survival of all groups and table of frequeat younger age and CRC was more advanced and in the right colon
[37]. In literature, high blood glucose level was associated with higher
risk of colon cancer in men [38]. Our results indicate longer survival
in men with CRC treated with metformin (Figure 1B), although it is
not statistically significant due to small number of patients in thisication (A) and carcinoma locations in colon (B), the p-value of
ncies of all patients.
Figure 3. Estimated survival functions for men and women, the p-value of log-rank test comparing survival and table of frequencies
of all patients treated by diet and other PAD (A) and patients treated with metformin and without (B).
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level combined with metformin or an action of this medication in the
microenvironment. Evaluating these findings in the context of
gender, genetic predisposition, physical activity, nutrition, and
hormones might prove a rewarding area for future investigation.
It is known that fibrocytic stromal transition is associated with local
invasiveness of CRC but it might be the mucinous mixture in stroma
responsible for molecular transition or interactions with tumorFigure 4. Estimated survival functions for different osteoporosi
comparing survival for all groups and table of frequencies of all pmicroenvironment that makes diseases to progress and contributes to
development of distant organ metastases. Stromal transformation
[39,40] and locally hypoxic tumor environment are both possible
factors underlying CRC progression at the tissue and cellular level
[41].
We identified numerous patients with CRC and with history of
long-term treatment for T2DM with specific peroral andiabetic
medication, including metformin. The majority of our patients weres (A) and other endocrinopathies (B), p-value of log-rank test
atients.
Figure 5. The incidence of endocrine comorbidities among CRC patients according to the distant metastases development.
390 Survival in colorectal adenocarcinoma in response to metformin Powell et al. Translational Oncology Vol. 13, No. 2, 2020on metformin for more than one year. The effect of metformin may
vary in CRC depending on duration of T2DM. The daily dose of
metformin in most patients was 850 mg which could suggest that
such a dose is sufficient to improve survival. In vivo testing in rats has
shown that metformin accumulates in tissues. It is not known if an
accumulation of medication could result in a more pronounced effect.
Laboratory models show antineoplastic activity of metformin, but
metformin concentrations used in many experiments exceed those
achieved with conventional doses used for diabetes treatment. The
pharmacological effect of metformin includes respiration reduction of
cells ATP related [42] and mimics caloric restriction both in cells and
systemically, affecting production of metabolic hormones [43].
Decreased blood glucose levels in metformin patients, and possibly
a de novo synthesis of cholesterol through the intestinal MAPK
dependent pathway documented during in vitro studies, may lead to
tumor cell mitochondrial dysfunction and could explain the systemic
protective effect and improved survival in patients with well--
controlled diabetes, particularly in the metformin group. Some
studies found metformin to potentially promote the immune system
response against cancer [44]. Adjuvant therapy with metformin has
been observed having positive impact in pancreatic, lung, and liver
malignancies, but not in breast and prostate cancer [45,46]. The
systematic analysis at biochemical markers and morphology char-
acteristics in correlated CRC specimens (proliferative index, stroma
type) might be useful to assess.
Estrogen alone has the proinflammatory effect in colon and can
have various effects at tumorigenesis in vivo [47]. It has been shown
that female hormones, estrogen and medroxyprogesterone acetate,
reduced the number of colon cancer in postmenopausal women by
37% compare with placebo in 5-year interval [48,49]. Osteoporosis
not only contributes to more advanced local disease in CRC but also
negatively advances CRC progression. The impact of osteoporosis in
the course of CRC can also relate to estrogen and testosterone. The
blood levels of these hormones are known to be reduced by
metformin. Recent clinical data showed that hormone replacement
therapy (HRT) in women might reduce CRC risk, suggesting
possible opportunities for translational research [50]. Growth
hormone (GH) therapy and autonomous hyperproduction of GH
together with increased level of IGF-1 are associated with a higher riskfor CRC, and close follow-up for these patients is highly advised [51].
Hypothyroidism did not correlate with survival in CRC patients,
possibly because of long-term thyroid hormone replacement in all
patients and two-thirds of CRC patients being men in whom
thyroiditis is much less frequent.Conclusion
We provide evidence in this large retrospective study from Central
Europe that, while diabetes is associated with a higher risk for CRC
impacting the incidence, T2DM as comorbidity does not
significantly impact survival among CRC patients and contrary,
peroral treatment due to T2DM, particularly metformin, demon-
strates improved survival in CRC. We emphasize that evaluation of
location of primary tumor and histopathologic characteristics is
essential for assessment of prognosis for patients with CRC, and it is
also of great value to consider the complete clinical profile of each
patient, including the medication history, as this may impact the
cancer environment. Improved understanding of the effect of
metabolic disorders coexisting with cancer and their pharmacologic
targeting could lead to better screening methods and updated
treatment guidelines to improve outcomes for patients with
colorectal cancer.Funding
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